Skip to main content

New TAU study tracks coronavirus spread patterns in Israel

Written on |

Research finds approximately 70% of the infections in Israel were caused by a SARS-CoV2 strain imported from the United States

A  team of Tel Aviv University researchers led by Dr. Adi Stern of the School of Molecular Cell Biology and Biotechnology at TAU’s George S. Wise Faculty of Life Sciences have conducted the first large-scale genomic sequencing of the novel coronavirus strain that has infected to date over 16,500 people in Israel. The scientists harnessed their genomic map to pinpoint mutations indicating where the virus originated from and later spread to within Israel. The study is based on an analysis of the genomic sequences of over 200 patients at hospitals across Israel, who together constitute a representative sample of the general population. TAU doctoral students Daniel Miller, Noam Harel, Talia Kostin, Omer Tirosh and Moran Meir conducted the research for the study in collaboration with scientists at Emory University, Gertner Institute, Chaim Sheba Medical Center, the Holon Institute of Technology, Assuta Hospital Ashdod, Hadassah Ein Karem Medical Center, Soroka Medical Center, Barzilai Medical Center, Poriya Medical Center, and the Genome Center at the Technion Institute of Technology.

The origins of coronavirus

“The novel coronavirus is characterized by mutations that occur at a set pace,” explains Dr. Stern. “These mutations do not affect the virus, i.e. it remains stable, but these mutations can help us trace the chain of infection from country to country. After the pandemic broke out in Wuhan, for example, one or two mutations occurred, and one virus with a mutation may have migrated to Europe where it experienced additional mutations, and from there it traveled to the United States, and so on. “We can look at these mutations as a kind of barcode that helps us keep track of the progression and transformation of the coronavirus as it moves from country to country.” To obtain a clear picture of the origin of infection in Israel, the researchers compared the genomic sequences of local patients to some 4,700 genomic sequences taken from patients around the world. They found that more than 70% of the patients had been infected by a coronavirus strain that originated in the U.S. The remaining nearly 30% of infections were imported from Europe and elsewhere: Belgium (8%), France (6%), England (5%), Spain (3%), Italy (2%), the Philippines (2%), Australia (2%) and Russia (2%). According to Dr. Stern, the new genomic map provides insight into the precise spread of the novel coronavirus within Israel. Until now, any assessment of the spread of infection relied on such subjective parameters as patient feedback. The new research will be able to expose the rate of infection in a household, in an apartment building, in a school, in a neighborhood, and more. It will also provide early detection of super spreaders – people who travel far and wide and infect a large number of people – and could even identify major events with the potential to trigger widespread infection.

The importance of 10%

“Going forward, the data obtained from genomic sequencing will serve as an important basis for informed decisions about which institutions to close, for what amount of time, and in which format,” says Dr. Stern. With policymakers in mind, the researchers developed a complex statistical model based on genomic sequencing that estimates the epidemiological parameters of viral spread. The model shows that the rate of infection decreased significantly following strict quarantine measures taken in Israel and highlights a major discrepancy between the number of people each coronavirus patient infected. The model also estimates that over 80% of coronavirus cases in Israel were the direct result of only 10% of the coronavirus patients in Israel, meaning that these 10% were, in fact, super-spreaders. According to the model and to the genomic sequencing, Dr. Stern says that no more than 1% of the population in Israel contracted the virus – a far cry from herd immunity. “In our study, we performed the first massive genomic sequencing of the coronavirus in Israel,” she concludes. “This technology and the information it provides is of great importance for understanding the virus and its spread in the population, as a scientific and objective basis for local and national decision-making. The data obtained from the research can greatly help policymakers on issues such as closures and quarantines. In doing so, the study makes a significant contribution to dealing with the epidemic in Israel, and, more importantly: We have developed tools that will allow us to cope, in real time, with the next outbreak that may occur.”

Related posts

TAU Breakthrough Reveals Mechanism That Eliminates Tumors

3 November 2024

Could Cancer Vulnerabilities Be Hidden in Chromosome Changes?

23 September 2024

Spotting Parkinson’s Early: A New TAU Breakthrough

17 September 2024

How Can We See Through Closed Eyes?

16 September 2024

Can Parkinson’s Treatment be Enhanced by AI Tech?

1 September 2024

Want to Fall in Love? Step Outside in The Sun

19 August 2024

Can Smartwatches Prevent Pandemic Outbreaks?

7 August 2024

How Close Are We to Thought-Based Communication?

22 July 2024

Will Wearable Tech Transform Neurological Diagnosis?

21 July 2024

Will Existing Drugs Stop Cancer’s Bone Spread?

19 May 2024

Heart Disease’s Cancer Link Unveiled

14 April 2024

Do Green Environments Help Heart Patients Live Longer?

4 April 2024

TAU Receives $12.67M Grant for Medical Simulation Center

1 April 2024

Breaking the MedTech Glass Ceiling

27 March 2024

Summer Glow: How Sun Exposure Boosts Fertility in Women Ages 30-40

7 March 2024

Are We Close to Ending Alzheimer’s Memory Loss?

15 February 2024

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: [email protected]

New South Wales

Level 22, Westfield Tower 2, 101 Grafton Street, Bondi Junction NSW 2022
Phone: +61 418 465 556
Email: [email protected]

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: [email protected]